Clinical Trial Update: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade [Phase 2]

View source ↗

Summary

Open-label Phase 2 study to evaluate safety and efficacy of CCX168 in subjects with immunoglobulin A nephropathy on stable RAAS blockade; study completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• CCX168 (avacopan)

Snippet

Sponsor: Amgen | Conditions: Immunoglobulin A Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01